|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KCNA7 |
Gene summary for KCNA7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KCNA7 | Gene ID | 3743 |
| Gene name | potassium voltage-gated channel subfamily A member 7 | |
| Gene Alias | HAK6 | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q96RP8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3743 | KCNA7 | HCC1 | Human | Liver | HCC | 5.88e-14 | 1.41e+00 | 0.5336 |
| 3743 | KCNA7 | HCC2 | Human | Liver | HCC | 1.68e-19 | 1.40e+00 | 0.5341 |
| 3743 | KCNA7 | HCC5 | Human | Liver | HCC | 1.43e-27 | 1.69e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KCNA7 | SNV | Missense_Mutation | novel | c.796N>A | p.Gly266Arg | p.G266R | Q96RP8 | protein_coding | tolerated(0.06) | benign(0.134) | TCGA-A7-A5ZW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| KCNA7 | SNV | Missense_Mutation | c.1175N>G | p.Val392Gly | p.V392G | Q96RP8 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| KCNA7 | SNV | Missense_Mutation | rs745798209 | c.680N>A | p.Arg227His | p.R227H | Q96RP8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KCNA7 | SNV | Missense_Mutation | novel | c.1308N>T | p.Glu436Asp | p.E436D | Q96RP8 | protein_coding | tolerated_low_confidence(0.18) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| KCNA7 | SNV | Missense_Mutation | rs766196010 | c.928N>T | p.Arg310Cys | p.R310C | Q96RP8 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| KCNA7 | SNV | Missense_Mutation | novel | c.545N>A | p.Ala182Glu | p.A182E | Q96RP8 | protein_coding | tolerated(0.75) | benign(0) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| KCNA7 | SNV | Missense_Mutation | rs139571533 | c.988G>A | p.Val330Ile | p.V330I | Q96RP8 | protein_coding | tolerated(0.25) | benign(0.215) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| KCNA7 | SNV | Missense_Mutation | novel | c.736G>A | p.Asp246Asn | p.D246N | Q96RP8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| KCNA7 | SNV | Missense_Mutation | rs531366512 | c.631G>A | p.Val211Met | p.V211M | Q96RP8 | protein_coding | tolerated(0.26) | benign(0.275) | TCGA-AP-A0LD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KCNA7 | SNV | Missense_Mutation | novel | c.1281N>T | p.Lys427Asn | p.K427N | Q96RP8 | protein_coding | tolerated_low_confidence(0.29) | benign(0.007) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3743 | KCNA7 | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL2107762 | NERISPIRDINE | |
| 3743 | KCNA7 | ION CHANNEL, DRUGGABLE GENOME | blocker | 135649937 | AMIODARONE | |
| 3743 | KCNA7 | ION CHANNEL, DRUGGABLE GENOME | blocker | 135651305 | VERAPAMIL | |
| 3743 | KCNA7 | ION CHANNEL, DRUGGABLE GENOME | blocker | 135650266 | FLECAINIDE | |
| 3743 | KCNA7 | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL113461 | TEDISAMIL | |
| 3743 | KCNA7 | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL284348 | DALFAMPRIDINE | |
| 3743 | KCNA7 | ION CHANNEL, DRUGGABLE GENOME | blocker | CHEMBL1200728 | GUANIDINE HYDROCHLORIDE | |
| 3743 | KCNA7 | ION CHANNEL, DRUGGABLE GENOME | blocker | 135650872 | QUINIDINE | |
| 3743 | KCNA7 | ION CHANNEL, DRUGGABLE GENOME | blocker | 135651249 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |